These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37245833)

  • 1. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models.
    Vinueza-Gavilanes R; Bravo-González JJ; Basurco L; Boncristiani C; Fernández-Irigoyen J; Santamaría E; Marcilla I; Pérez-Mediavilla A; Luquin MR; Vales A; González-Aseguinolaza G; Aymerich MS; Aragón T; Arrasate M
    Neurobiol Dis; 2023 Jul; 183():106166. PubMed ID: 37245833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation.
    Íñigo-Marco I; Valencia M; Larrea L; Bugallo R; Martínez-Goikoetxea M; Zuriguel I; Arrasate M
    Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8274-E8283. PubMed ID: 28900007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal acetylation mutants affect alpha-synuclein stability, protein levels and neuronal toxicity.
    Vinueza-Gavilanes R; Íñigo-Marco I; Larrea L; Lasa M; Carte B; Santamaría E; Fernández-Irigoyen J; Bugallo R; Aragón T; Aldabe R; Arrasate M
    Neurobiol Dis; 2020 Apr; 137():104781. PubMed ID: 31991248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha synuclein processing by MMP-3 - implications for synucleinopathies.
    Bluhm A; Schrempel S; Moceri S; Stieler J; Feja M; Schilling S; Schulze A; von Hörsten S; Hartlage-Rübsamen M; Richter F; Roßner S
    Behav Brain Res; 2022 Sep; 434():114020. PubMed ID: 35870616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
    Svarcbahs R; Julku UH; Myöhänen TT
    J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
    Mavroeidi P; Arvanitaki F; Karakitsou AK; Vetsi M; Kloukina I; Zweckstetter M; Giller K; Becker S; Sorrentino ZA; Giasson BI; Jensen PH; Stefanis L; Xilouri M
    Acta Neuropathol; 2019 Sep; 138(3):415-441. PubMed ID: 31011860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular Prion Protein Mediates α-Synuclein Uptake, Localization, and Toxicity In Vitro and In Vivo.
    Thom T; Schmitz M; Fischer AL; Correia A; Correia S; Llorens F; Pique AV; Möbius W; Domingues R; Zafar S; Stoops E; Silva CJ; Fischer A; Outeiro TF; Zerr I
    Mov Disord; 2022 Jan; 37(1):39-51. PubMed ID: 34448510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
    Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
    Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggregated Alpha-Synuclein Inclusions within the Nucleus Predict Impending Neuronal Cell Death in a Mouse Model of Parkinsonism.
    Weston LJ; Bowman AM; Osterberg VR; Meshul CK; Woltjer RL; Unni VK
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.
    Schildknecht S; Gerding HR; Karreman C; Drescher M; Lashuel HA; Outeiro TF; Di Monte DA; Leist M
    J Neurochem; 2013 May; 125(4):491-511. PubMed ID: 23452040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein.
    Landeck N; Strathearn KE; Ysselstein D; Buck K; Dutta S; Banerjee S; Lv Z; Hulleman JD; Hindupur J; Lin LK; Padalkar S; Stanciu LA; Lyubchenko YL; Kirik D; Rochet JC
    Mol Neurodegener; 2020 Sep; 15(1):49. PubMed ID: 32900375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
    Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
    Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy.
    Lin S; Leitão ADG; Fang S; Gu Y; Barber S; Gilliard-Telefoni R; Castro A; Sung K; Shen R; Florio JB; Mante ML; Ding J; Spencer B; Masliah E; Rissman RA; Wu C
    Neurobiol Dis; 2023 Mar; 178():106010. PubMed ID: 36702318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
    Ysselstein D; Dehay B; Costantino IM; McCabe GP; Frosch MP; George JM; Bezard E; Rochet JC
    Acta Neuropathol Commun; 2017 Jan; 5(1):3. PubMed ID: 28069058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nurr1 repression mediates cardinal features of Parkinson's disease in α-synuclein transgenic mice.
    Argyrofthalmidou M; Spathis AD; Maniati M; Poula A; Katsianou MA; Sotiriou E; Manousaki M; Perier C; Papapanagiotou I; Papadopoulou-Daifoti Z; Pitychoutis PM; Alexakos P; Vila M; Stefanis L; Vassilatis DK
    Hum Mol Genet; 2021 Jul; 30(16):1469-1483. PubMed ID: 33902111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REST Protects Dopaminergic Neurons from Mitochondrial and α-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model.
    Ryan BJ; Bengoa-Vergniory N; Williamson M; Kirkiz E; Roberts R; Corda G; Sloan M; Saqlain S; Cherubini M; Poppinga J; Bogtofte H; Cioroch M; Hester S; Wade-Martins R
    J Neurosci; 2021 Apr; 41(16):3731-3746. PubMed ID: 33563726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of an aggregation-prone variant of alpha-synuclein used to model synucleinopathies.
    Masaracchia C; König A; Valiente-Gabioud AA; Peralta P; Favretto F; Strohäker T; Lázaro DF; Zweckstetter M; Fernandez CO; Outeiro TF
    Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140298. PubMed ID: 31676453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity.
    Ferreira DG; Batalha VL; Vicente Miranda H; Coelho JE; Gomes R; Gonçalves FQ; Real JI; Rino J; Albino-Teixeira A; Cunha RA; Outeiro TF; Lopes LV
    Cereb Cortex; 2017 Jan; 27(1):718-730. PubMed ID: 26534909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
    Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
    Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.